Ultragenyx to Participate in Investor Conferences in December
Ultragenyx to Participate in Investor Conferences in December
NOVATO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming investor conferences.
加利福尼亚州诺瓦托，2024年11月26日(GLOBE NEWSWIRE) -- ultragenyx pharmaceutical公司(NASDAQ: RARE)，一家专注于开发和商业化罕见和超罕见遗传病新疗法的生物制药公司，今天宣布将参加三个即将举行的投资者会议。
Citi's 2024 Global Healthcare Conference (Miami, FL)
花旗银行2024全球医疗保健会议(迈阿密，佛罗里达州)
- Tuesday, December 3, 2024, Emil Kakkis, M.D., Ph.D., CEO and President and Howard Horn, Chief Financial Officer, will participate in a fireside chat and host 1x1 meetings.
- 2024年12月3日星期二，首席执行官和总裁Emil Kakkis万.D.博士以及首席财务官Howard Horn将参加炉边聊天，并举行1x1会议。
7th Annual Evercore ISI HealthCONx Conference (Coral Gables, FL)
第七届年度evercore ISI HealthCONx会议(科勒盖布尔斯，佛罗里达州)
- Wednesday, December 4, 2024, Emil Kakkis and Howard Horn will participate in a fireside chat and host 1x1 meetings.
- 2024年12月4日星期三，Emil Kakkis和Howard Horn将参加炉边聊天，并举行1x1会议。
Piper Sandler's 36th Annual Healthcare Conference (New York, NY)
派杰投资第36届医疗会议(纽约，纽约)
- Thursday, December 5, 2024, Eric Crombez, M.D., Chief Medical Officer and Howard Horn will participate in a fireside chat and host 1x1 meetings.
- 周四，2024年12月5日，首席医疗官Eric Crombez博士和霍华德·霍恩将参加炉边聊天，并举行1x1会议。
The live and archived webcast of the fireside chats will be accessible from the company's website at
炉边聊天的现场直播和存档将可从该公司网站访问。
About Ultragenyx Pharmaceutical Inc.
关于Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
Ultragenyx是一家生物制药公司，致力于为罕见的和极其罕见的遗传病提供新型治疗产品。该公司已构建了一个多样化的批准治疗方案和产品候选组合，旨在解决存在高需求和明确生物学治疗的疾病，而通常没有治疗相关潜在疾病的批准治疗方案。
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
该公司由一支有丰富罕见病治疗药物开发和商业化经验的管理团队领导。Ultragenyx 的策略基于及时高效的药品研发，旨在以最大的紧迫性向患者提供安全有效的治疗。
For more information on Ultragenyx, please visit the company's website at: .
有关Ultragenyx的更多信息，请访问该公司的网站。
Contacts – Ultragenyx Pharmaceutical, Inc.
联系方式-医疗保健-Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
ir@ultragenyx.com
投资者
Joshua Higa
ir@ultragenyx.com
